Jingzhen Medical Completes RMB 100 Million Series B1 Financing to Advance Digital Twin-Driven Precision Surgery

In recent years, precision medicine has become a focal point for both the healthcare industry and capital markets. This year, TrueSight completed its Series B1 financing round, raising hundreds of millions of yuan. The round was jointly invested by Qirong Venture Capital and the Zhongguancun Zhiyou Scientist Fund. To date, all four of TrueSight’s financing rounds have seen follow-on investments from existing shareholders, demonstrating strong market recognition of its products and confidence in the company’s sustained business growth.

Regarding this financing round, TrueSight stated that the funds will be primarily allocated to R&D investment in product technology, with a focus on deepening the application of digital twin technology in other surgical scenarios, establishing a comprehensive presence across the entire clinical surgery value chain, and driving the advancement of precision medicine paradigms.

With over 20 million surgical procedures performed annually in China, the surgical market is substantial. In response to the limitations of current technologies and the complexities of individual patient differences, TrueSight was founded with the mission of providing leading digital precision solutions for surgeons. TrueSight pioneered the concept of Digital Twin organs globally and established a comprehensive Digital Twin platform framework. By deeply integrating artificial intelligence algorithms into its software architecture, it has overcome the bottlenecks of traditional technologies in processing such imaging data. Through bidirectional information interaction between patients’ real organs and their virtual Digital Twin counterparts, the system provides surgical experts with precise, standardized operative guidance in real time. Compared to traditional experience-based surgery, precision surgery enabled by the Digital Twin Clinical Surgical Decision Support System reduces surgical planning time from two hours to just 15 minutes and increases accuracy from 75% to 97%. Clinical trials have demonstrated that the use of this system significantly shortens procedure duration, reduces intraoperative blood loss, and lowers postoperative adverse reactions, thereby revolutionizing the functionality and efficiency of preoperative surgical planning.

Over the past three years, TrueSight has remained steadfastly focused on “addressing genuine clinical needs,” continuously updating and iterating its core products while advancing commercialization. To date, multiple products have obtained registration certificates from China’s National Medical Products Administration (NMPA), with seven additional NMPA approvals expected within the year. TrueSight’s products are now deployed in more than 100 medical institutions across China, achieving comprehensive coverage across hospitals of all tiers. As essential tools for hospitals, they have provided high-precision, fully quantitative preoperative surgical planning services to tens of thousands of patients.

Academician Dong Jiahong of Beijing Tsinghua Changgung Hospital commented, “This system integrates artificial intelligence technology with the concept of precision surgery, enabling rapid, fully automated, and high-precision organ reconstruction, which significantly enhances the accuracy and efficiency of systematic anatomical, pathological, and physiological assessments.”

Secured Four Rounds of Funding in Three Years, Raising Over RMB 150 Million. TrueSight addresses the critical clinical needs of precise surgical treatment by providing accurate solutions for thoracic, hepatobiliary, urological, and other surgical procedures. Meanwhile, actively fulfilling its social responsibilities during the COVID-19 pandemic, the company collaborated with Tsinghua University and multiple leading hospitals to urgently develop a system that completed chest CT screening and comprehensive analysis for a large number of suspected cases in a short period. This significantly reduced the workload of clinicians and radiologists, enabled precise disease classification, and facilitated rapid triage and treatment of patients.

Under the 14th Five-Year Plan, “Next-Generation Artificial Intelligence” has become a key driver for economic transformation and upgrading as well as for achieving self-reliance and strength in science and technology. TrueSight will continue to actively explore the in-depth support of Digital Twin technology in other clinical domains, aiming to build a comprehensive, precision surgical assistant for clinical surgery.

TrueSight has completed four rounds of financing in just three years. This not only reflects the positive momentum of the medical technology industry, but also serves as a strong endorsement of TrueSight’s product capabilities and its current development trajectory.

Yu Yongping, General Manager of Qirong Venture Capital: “We consistently focus on the commercialization of scientific research achievements from top-tier universities and projects integrating medicine with engineering, aiming to promote deep integration between technology and capital to achieve genuine innovative development. TrueSight has always adhered to the deep integration of industry, academia, and research, establishing a virtuous, interactive system for translating technological achievements into practical applications, with an emphasis on product refinement and iteration speed. We believe that TrueSight’s products and technologies hold significant potential for expansion and integration in certain niche areas of digital surgery, and we look forward to the company continuing to deliver novel smart solutions to clinical surgical practice.”

Professor Wang Tianmiao of Beihang University, Chief Expert Advisor to the Zhongguancun Zhiyou Scientist Fund: We remain highly optimistic about the application prospects of artificial intelligence in the medical field. Leveraging its technological strength and advanced philosophy, TrueSight started with surgical planning for hepatobiliary procedures and has step by step developed a series of AI products that address critical clinical needs. Its business has expanded to multiple departments, including thoracic surgery and neurosurgery, and now serves nearly one hundred hospitals across China. The company has initially established a fan-shaped architecture in its product matrix and application scenarios, emerging as a leader in the digital clinical surgery sector. We invested in its Series A round in 2019 and have continued to increase our investment in each subsequent financing round. We believe that TrueSight will remain a leading enterprise in the AI-driven digital surgery industry, continuously creating value for clinical practice and society.